Evidence map›Paper›PMID 41309537›Full record

ArticleHuman genome variation2025

DNA methylation data from Japanese patients with Rubinstein-Taybi syndrome.

Tomoko Kawai, Taiga Aoki, Kazuhiko Nakabayashi, Kenichiro Hata, Tadashi Kaname, Rika Kosaki

Abstract read
In one paragraph

Article in Human genome variation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomoko KawaiDepartment of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo, Japan. kawai-tm@ncchd.go.jp.ORCID http://orcid.org/0000-0001-8137-0334
Taiga AokiDepartment of Genome Medicine, National Center for Child Health and Development, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6043-9355
Kazuhiko NakabayashiDepartment of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo, Japan.
Kenichiro HataDepartment of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo, Japan.
Tadashi KanameDepartment of Genome Medicine, National Center for Child Health and Development, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0281-9610
Rika KosakiDivision of Medical Genetics, National Center for Child Health and Development, Tokyo, Japan. kosaki-r@ncchd.go.jp.

Funding

Japan Agency for Medical Research and Development (AMED) 25ek0109672s01Japan Agency for Medical Research and Development (AMED) 25ek0109672s03Japan Agency for Medical Research and Development (AMED) 25ek0109760s0202
6 · The paper itself

Abstract

An episignature is a genome-wide DNA methylation pattern that is specific to each syndrome or etiologic gene. Episignature analysis helps to diagnose patients with variants of uncertain significance (VUS), but this requires positive methylation datasets from patients with a definitive diagnosis. Here we provide methylation datasets of Rubinstein-Taybi syndrome at the individual patient level, which have not been published before. This dataset increases the likelihood of determining the function of the VUS.

Identifiers

PMID41309537
PMCPMC12660993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.